过敏诊断市场机会、成长动力、产业趋势分析与 2025 - 2034 年预测

2024 年全球过敏诊断市场价值为 66 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 10.9%，这主要得益于气喘、鼻炎和食物过敏等过敏症的盛行率不断上升。随着生活方式的改变、污染水平的上升和环境触发因素的增多，对准确、有效的过敏测试解决方案的需求从未如此高涨。多重检测和免疫测定等诊断技术的快速进步正在透过提高精确度、效率和患者舒适度彻底改变过敏测试。这些创新使医疗保健提供者能够以更快的速度和更高的准确性检测更广泛的过敏原，确保及时有效地管理患者。

过敏性疾病影响全球数百万人，其日益加重的经济负担也推动了市场的扩张。医疗保健提供者和研究机构正在积极投资先进的诊断工具，以改善早期检测和个人化治疗方法。人们对早期诊断益处的认识不断提高，加上医疗保健支出的不断增加，进一步推动了对复杂过敏测试解决方案的需求。此外，实验室越来越多地采用自动化技术，简化了过敏诊断流程，减少了人为错误，提高了测试的可重复性，使过敏测试更加方便和可靠。

过敏诊断市场依产品和服务分为消耗品、仪器和服务。其中，预计消耗品将占据市场主导地位，年复合成长率为 10.8%，到 2034 年将达到 102 亿美元。过敏性疾病的盛行率不断上升，加上其高昂的医疗费用，推动了对试剂和检测试剂盒等消耗品的需求。由于环境变化导致过敏现象越来越普遍，对能够准确识别过敏原的先进诊断解决方案的需求也日益增加。

就测试类型而言，市场分为体内测试和体外测试。预计体内测试部分将为市场扩张做出重大贡献，年复合成长率为 10.6%，到 ​​2034 年将超过 96 亿美元。皮肤点刺试验和皮内测试对于诊断各种过敏症仍然至关重要，因为它们可以提供快速、可靠的结果。它们价格实惠、准确且易于在临床环境中使用，使其成为医疗保健专业人士的首选。这些测试对于检测环境因素、食物和昆虫毒液引起的过敏特别有效，进一步推动了它们的应用。

美国过敏诊断市值在 2024 年将达到 23 亿美元，预计在 2025 年至 2034 年期间的复合年增长率为 10.2%。该国过敏症发病率的不断上升、医疗服务提供者和患者意识的不断增强以及向个人化治疗方法的日益转变是推动市场成长的关键因素。对精确诊断工具的需求不断增长，加上强大的医疗保健基础设施和技术进步，进一步增强了市场前景。随着过敏相关疾病的持续增加，美国市场有望大幅扩张，为诊断製造商和医疗保健提供者提供有利可图的机会。

目录

第 1 章：方法论与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 过敏性疾病盛行率不断上升，经济负担沉重
    • 污染加剧，呼吸道疾病增多
    • 过敏诊断公司融资增加
    • 儿童过敏意识
    • 新产品的技术进步
  • 产业陷阱与挑战
    • 过敏诊断仪价格昂贵
    • 对过敏性疾病的认识有限
• 成长潜力分析
• 监管格局
• 技术格局
• 差距分析
• 波特的分析
• PESTEL 分析
• 未来市场趋势
• 价值链分析
• 过敏诊断与管理的创新
• 食物过敏诊断的未来
• 人工智慧增强过敏诊断

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第 5 章：市场估计与预测：按产品和服务，2021 年至 2034 年

• 主要趋势
• 耗材
• 仪器
• 服务

第六章：市场估计与预测：按测试类型，2021 年至 2034 年

• 主要趋势
• 体内
  • 皮肤点刺试验
  • 皮内皮肤试验
  • 其他体内测试类型
• 体外

第 7 章：市场估计与预测：按过敏原，2021 — 2034 年

• 主要趋势
• 吸入过敏原
• 食物过敏原
• 药物过敏原
• 其他过敏原

第 8 章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 诊断实验室
• 医院实验室
• 其他最终用户

第九章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• BIOMERIEUX
• danaher
• eurofins
• EUROIMMUN
• HITACHI
• HOB
• hycor
• LINCOLN Diagnostics INC.
• MINARIS Medical
• NEOGEN CORPORATION
• Omega DIAGNOSTICS GROUP PLC
• r-biopharm
• SIEMENS Healthcare Diagnostics
• STALLERGENES
• Thermo Fisher SCIENTIFIC

The Global Allergy Diagnostics Market was valued at USD 6.6 billion in 2024 and is projected to expand at a CAGR of 10.9% between 2025 and 2034, driven by an increasing prevalence of allergic conditions such as asthma, rhinitis, and food allergies. With changing lifestyles, rising pollution levels, and growing environmental triggers, the demand for accurate and efficient allergy testing solutions has never been higher. The rapid advancements in diagnostic technologies, including multiplex assays and immunoassays, are revolutionizing allergy testing by improving precision, efficiency, and patient comfort. These innovations allow healthcare providers to detect a broader range of allergens with enhanced speed and accuracy, ensuring timely and effective patient management.

The market expansion is also fueled by the increasing economic burden of allergic diseases, which affect millions of individuals worldwide. Healthcare providers and research institutions are actively investing in advanced diagnostic tools to improve early detection and personalized treatment approaches. The growing awareness about the benefits of early diagnosis, coupled with rising healthcare expenditures, is further driving demand for sophisticated allergy testing solutions. In addition, the increasing adoption of automation in laboratories is streamlining allergy diagnostics, reducing human error, and enhancing test reproducibility, making allergy testing more accessible and reliable.

The allergy diagnostics market is classified by product and service into consumables, instruments, and services. Among these, consumables are expected to dominate the market, growing at a CAGR of 10.8% and reaching USD 10.2 billion by 2034. The rising prevalence of allergic diseases, combined with their substantial healthcare costs, is fueling demand for consumables, including reagents and test kits. With allergies becoming more widespread due to environmental changes, the need for advanced diagnostic solutions that offer accurate allergen identification is increasing.

In terms of test type, the market is categorized into in vivo and in vitro tests. The in vivo segment is projected to contribute significantly to market expansion, growing at a CAGR of 10.6% and surpassing USD 9.6 billion by 2034. Skin prick tests and intradermal tests remain essential for diagnosing various allergies, as they provide quick, reliable results. Their affordability, accuracy, and ease of use in clinical settings make them a preferred choice among healthcare professionals. These tests are particularly effective in detecting allergies caused by environmental factors, food, and insect venom, further driving their adoption.

The U.S. allergy diagnostics market, valued at USD 2.3 billion in 2024, is expected to grow at a CAGR of 10.2% between 2025 and 2034. The country's increasing rates of allergic conditions, heightened awareness among healthcare providers and patients, and the growing shift toward personalized treatment approaches are key factors propelling market growth. The rising need for accurate diagnostic tools, combined with strong healthcare infrastructure and technological advancements, is further strengthening the market outlook. As allergy-related disorders continue to rise, the U.S. market is poised for substantial expansion, providing lucrative opportunities for diagnostic manufacturers and healthcare providers alike.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence and high economic burden of allergic diseases
    • 3.2.1.2 Growing pollution levels coupled with rise in respiratory disorders
    • 3.2.1.3 Rise in funding for allergy diagnostics companies
    • 3.2.1.4 Pediatric allergy awareness
    • 3.2.1.5 Technological advancements in new products
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of allergy diagnostic instrument
    • 3.2.2.2 Limited awareness related to allergic diseases
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Gap analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Value chain analysis
• 3.11 Innovations in allergy diagnostics and management
• 3.12 The future of food allergy diagnosis
• 3.13 AI-enhanced allergy diagnostics

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product and Service, 2021 — 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Consumables
• 5.3 Instruments
• 5.4 Services

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 — 2034 ($ Mn)

• 6.1 Key trends
• 6.2 In Vivo
  • 6.2.1 Skin prick tests
  • 6.2.2 Intradermal skin test
  • 6.2.3 Other in vivo test types
• 6.3 In Vitro

Chapter 7 Market Estimates and Forecast, By Allergen, 2021 — 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Inhaled allergens
• 7.3 Food allergens
• 7.4 Drug allergens
• 7.5 Other allergens

Chapter 8 Market Estimates and Forecast, By End Use, 2021 — 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Diagnostic laboratories
• 8.3 Hospital-based laboratories
• 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 — 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 BIOMERIEUX
• 10.2 danaher
• 10.3 eurofins
• 10.4 EUROIMMUN
• 10.5 HITACHI
• 10.6 HOB
• 10.7 hycor
• 10.8 LINCOLN Diagnostics INC.
• 10.9 MINARIS Medical
• 10.10 NEOGEN CORPORATION
• 10.11 Omega DIAGNOSTICS GROUP PLC
• 10.12 r-biopharm
• 10.13 SIEMENS Healthcare Diagnostics
• 10.14 STALLERGENES
• 10.15 Thermo Fisher SCIENTIFIC